Suzhou Yabao Pharmaceutical R&D Co., Ltd.
12
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
SY007 in Patients With Acute Ischemic Stroke
Role: lead
The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus
Role: lead
A Drug Interaction Study of SY-004 Capsules in Healthy Subjects
Role: lead
The Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus
Role: lead
Multiple Ascending Doses of SY-008 in Type 2 Diabetes Mellitus
Role: lead
A Food-drug Interaction Study of SY-004 in Healthy Subjects
Role: lead
Multiple Ascending Doses of SY-009 in Type 2 Diabetes Mellitus
Role: lead
SY-005 （Recombinant Human Annexin A5）in Patients With Sepsis
Role: lead
Single-dose/Multiple-doses Incremental Intravenous Injection of SY-005 （Recombinant Human Annexin A5）in Healthy Subjects
Role: lead
Single-dose Incremental Intravenous Injection of SY-007 in Healthy Subjects
Role: lead
Single Ascending Oral Doses of SY-009 in Healthy Subjects
Role: lead
Single Ascending Oral Doses of SY-008 in Healthy Subjects
Role: lead
All 12 trials loaded